News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CSPC Pharmaceutical Group Out-Licenses Western Rights For Cancer Drug To Dexcel


5/13/2014 8:16:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 12, 2014 -- CSPC Pharmaceutical Group, headquartered in China's Heibei Province, has partnered with Dexcel Pharma Technologies to co-develop and commercialize a generic oncology drug in the US, Europe and elsewhere. Dexcel is a privately held Israeli generic drug company, with a presence in more than 30 countries. Dexcel will pay CSPC $2 million to defray the pre-clinical and cGMP compliance certification costs. It will also be liable for up to $5 million in milestones, and Dexcel will be responsible for obtaining approvals of the product. More details....

Stock Symbol: (HK: 1093)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES